Hans Salwender

8.7k total citations · 1 hit paper
66 papers, 1.7k citations indexed

About

Hans Salwender is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Hans Salwender has authored 66 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Hematology, 31 papers in Molecular Biology and 25 papers in Oncology. Recurrent topics in Hans Salwender's work include Multiple Myeloma Research and Treatments (41 papers), Protein Degradation and Inhibitors (25 papers) and Cancer Treatment and Pharmacology (13 papers). Hans Salwender is often cited by papers focused on Multiple Myeloma Research and Treatments (41 papers), Protein Degradation and Inhibitors (25 papers) and Cancer Treatment and Pharmacology (13 papers). Hans Salwender collaborates with scholars based in Germany, United States and United Kingdom. Hans Salwender's co-authors include Hartmut Goldschmidt, Dieter Buchheidt, Gerlinde Egerer, E. Miltner, Kenshi Suzuki, Jeremy A. Ross, Birte Friedrichs, Markus Tiemann, Karl Verpoort and Philippe Moreau and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hans Salwender

57 papers receiving 1.6k citations

Hit Papers

Venetoclax or placebo in combination with bortezomib and ... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    2020 256 citations Shaji Kumar, Simon J. Harrison et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hans Salwender Germany 23 862 650 617 254 245 66 1.7k
J Treleaven United Kingdom 22 1.2k 1.4× 256 0.4× 474 0.8× 170 0.7× 209 0.9× 60 1.8k
César O. Freytes United States 30 1.0k 1.2× 348 0.5× 830 1.3× 189 0.7× 203 0.8× 82 2.2k
Marcus Hentrich Germany 27 275 0.3× 274 0.4× 1.1k 1.7× 498 2.0× 132 0.5× 98 2.3k
Hans‐Heinrich Wolf Germany 20 347 0.4× 190 0.3× 427 0.7× 480 1.9× 91 0.4× 42 1.3k
Prakash Vishnu United States 20 297 0.3× 247 0.4× 274 0.4× 139 0.5× 58 0.2× 67 1.4k
Monica Bhatia United States 26 1.0k 1.2× 243 0.4× 363 0.6× 203 0.8× 276 1.1× 120 1.8k
Georg Stüssi Switzerland 25 981 1.1× 388 0.6× 343 0.6× 220 0.9× 241 1.0× 96 2.1k
Mike Potter United Kingdom 24 823 1.0× 157 0.2× 409 0.7× 510 2.0× 242 1.0× 63 1.7k
Mark Cook United Kingdom 25 1.7k 2.0× 1.1k 1.7× 540 0.9× 203 0.8× 227 0.9× 90 2.7k
Kyoo‐Hyung Lee South Korea 29 1.6k 1.9× 532 0.8× 733 1.2× 300 1.2× 433 1.8× 168 2.6k

Countries citing papers authored by Hans Salwender

Since Specialization
Citations

This map shows the geographic impact of Hans Salwender's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Salwender with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Salwender more than expected).

Fields of papers citing papers by Hans Salwender

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Salwender. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Salwender. The network helps show where Hans Salwender may publish in the future.

Co-authorship network of co-authors of Hans Salwender

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Salwender. A scholar is included among the top collaborators of Hans Salwender based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Salwender. Hans Salwender is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Beck, Susanne, Vladimı́r Beneš, Hans Salwender, et al.. (2023). RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma. Frontiers in Immunology. 14. 1286700–1286700. 3 indexed citations
5.
Elias, K., Stefanie Huhn, Alexandra M. Poos, et al.. (2023). Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer Journal. 13(1). 1–1. 20 indexed citations
6.
7.
Straka, Christian, Hans Salwender, Stefan Knop, et al.. (2021). Full or intensity‐reduced high‐dose melphalan and single or double autologous stem cell transplant with or without bortezomib consolidation in patients with newly diagnosed multiple myeloma. European Journal Of Haematology. 107(5). 529–542. 4 indexed citations
8.
Seckinger, Anja, Michael Heider, Martina Rudelius, et al.. (2021). MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Advances. 6(2). 515–520. 7 indexed citations
9.
Kumar, Shaji, Simon J. Harrison, Michèle Cavo, et al.. (2021). Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 84–84. 20 indexed citations
10.
Moreau, Philippe, Simon J. Harrison, Michèle Cavo, et al.. (2019). Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1888–1888. 28 indexed citations
11.
Hose, Dirk, Susanne Beck, Hans Salwender, et al.. (2019). Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. Journal of Hematology & Oncology. 12(1). 65–65. 6 indexed citations
12.
Penack, Olaf, Dieter Buchheidt, Maximilian Christopeit, et al.. (2014). Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Annals of Hematology. 93(7). 1083–1095. 62 indexed citations
13.
Breitkreutz, Iris, H M Lokhorst, Marc‐Steffen Raab, et al.. (2007). Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 21(6). 1294–1299. 40 indexed citations
14.
15.
Schlenk, Richard F., Ulrich Germing, Frank Hartmann, et al.. (2005). High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia. 19(6). 978–983. 30 indexed citations
16.
Buchheidt, Dieter, Oliver A. Cornely, Meinolf Karthaus, et al.. (2003). Central venous catheter (CVC)-related infections in neutropenic patients. Annals of Hematology. 82(0). S149–S157. 48 indexed citations
17.
18.
Hegenbart, Ute, et al.. (2001). Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone. Supportive Care in Cancer. 9(5). 380–385. 5 indexed citations
19.
Miltner, E. & Hans Salwender. (1995). Injury severity of restrained front seat occupants in car-to-car side impacts. Accident Analysis & Prevention. 27(1). 105–110. 11 indexed citations
20.
Hahn, Uwe, Hartmut Goldschmidt, Hans Salwender, Rainer Haas, & W. Hunstein. (1995). Large‐bore central venous catheters for the collection of peripheral blood stem cells. Journal of Clinical Apheresis. 10(1). 12–16. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J Treleaven Breakdown of academic impact, for papers by César O. Freytes Breakdown of academic impact, for papers by Marcus Hentrich Breakdown of academic impact, for papers by Hans‐Heinrich Wolf Breakdown of academic impact, for papers by Prakash Vishnu Breakdown of academic impact, for papers by Monica Bhatia Breakdown of academic impact, for papers by Georg Stüssi Breakdown of academic impact, for papers by Mike Potter Breakdown of academic impact, for papers by Mark Cook Breakdown of academic impact, for papers by Kyoo‐Hyung Lee
Rankless by CCL
2026